Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 25, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
August 21, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering Announces $25 Million Private Placement

Immuneering Announces $25 Million Private Placement
August 13, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
April 02, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
March 20, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 20, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

IMMUNEERING NAMES DR. IGOR MATUSHANSKY AS CHIEF MEDICAL OFFICER
February 03, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 07, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104
December 17, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 12, 2024 08:00 ET | Source: Immuneering Corporation

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma